The Journal of Immunology最新發(fā)布的文獻(xiàn)?” Persistent Zika Virus Clinical Susceptibility despite Reduced Viral Burden in Mice with Expanded Virus-Specific CD8+ T Cells Primed by Recombinant Listeria monocytogenes”?使用了BioXCell的anti-mouse IFNAR-1抗體, 這篇文獻(xiàn)研究數(shù)據(jù)強(qiáng)調(diào)了在開發(fā)針對寨卡病毒感染的疫苗中靶向其他適應(yīng)性免疫成分的必要性。

摘要：Vaccines against Zika virus (ZIKV) infection that target CD8+ T cells are of considerable interest because Abs may enhance infection susceptibility. However, whether CD8+ T cells are protective or promote susceptibility to clinical infection symptoms remains uncertain. To more precisely investigate ZIKV-specific CD8+ T cells in isolation, we engineered a Listeria monocytogenes–based vector to express a single MHC class I–restricted immune dominant peptide, E294–302, from ZIKV envelope protein. We show accumulation of activated ZIKV-specific CD8+ T cells primed by recombinant L. monocytogenes is associated with reductions in circulating virus levels after ZIKV challenge in type I IFN receptor–deficient mice and wildtype mice administered neutralizing Abs against type I IFN receptor. Interestingly, susceptibility to ZIKV clinical infection including weight loss and mortality each persists and is neither significantly improved nor worsened compared with isogenic L. monocytogenes–primed control mice. These data demonstrating persistent ZIKV clinical susceptibility despite reduced viral burden in mice with expanded virus-specific CD8+ T cells highlights the need for targeting other adaptive immune components in developing vaccines against ZIKV infection.

文章鏈接：https://www.jimmunol.org/content/205/2/447

?

?訂購詳情：

詳情請咨詢?BioXcell?中國授權(quán)代理-欣博盛生物科技

全國服務(wù)熱線: 4006-800-892 ???????????郵箱: market@neobioscience.com

深圳: 0755-26755892 ?????北京: 010-88594029 ?????上海: 021-34613729 ?????????

廣州：18024516375 ???????香港: 852-69410778

代理品牌網(wǎng)站: www.nbs-bio.com

自主品牌網(wǎng)站: www.neobioscience.net